Sun, Feb 1, 2015, 1:49 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

ImmunoCellular Therapeutics, Ltd. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • fansteman fansteman Nov 24, 2012 7:54 AM Flag

    IMUC vs. NWBio

    Again: My impression is, if NWBio ever made it to the finishing line, their product does not look competitive even if at par with IMUC in regards to efficacy (which they won't be: ICT-107 phase II PE is mOS while DCVax phase III PE is mPFS). Tumor tissue logistics is a big obstacle - see Provenge - plus the additional costs and additional aphereses etc. But my biggest concern remains their phase III trial performance... A clinical trial running for more than 6 years and still recruiting (new centers and patients) is worrying for many reasons.

    My only other bet in the glioma space besides IMUC is Celldex (CLDX). Looks very promising in a sub-population of EGFRvIII-mutation positive patients (about 30% of all first-line GBM). In addition, they have a nicely diversified clinical portfolio in different indications... Take a look, Alexp!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.690.00(+0.19%)Jan 30 4:01 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.